Dr. Reddy’s Announces the Launch of Zoledronic Acid Injection
Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has
launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic
version of Zometa® (zoledronic acid) 4 mg/5 mL Injection in
the US market on March 4, 2013, following the approval by the United
States Food & Drug Administration (USFDA) of Dr. Reddy’s ANDA for
Zoledronic Acid Injection (4 mg/5 mL).
Dr. Reddy’s Zoledronic Acid Injection 4 mg/5mL is available in a single
use vial of concentrate.
Disclaimer
This press release includes forward-looking statements, as defined in
the U.S. Private Securities Litigation Reform Act of 1995. We have based
these forward-looking statements on our current expectations and
projections about future events. Such statements involve known and
unknown risks, uncertainties and other factors that may cause actual
results to differ materially. Such factors include, but are not limited
to, changes in local and global economic conditions, our ability to
successfully implement our strategy, the market acceptance of and demand
for our products, our growth and expansion, technological change and our
exposure to market risks. By their nature, these expectations and
projections are only estimates and could be materially different from
actual results in the future.
About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical
Services and Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics, biosimilars,
differentiated formulations and NCEs. Therapeutic focus is on
gastro-intestinal, cardiovascular, diabetology, oncology, pain
management, anti-infective and pediatrics. Major markets include India,
USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New
Zealand. For more information, log on to: www.drreddys.com
Zometa® is a registered trademark of Novartis AG